Our Department

Department Alumni Fest 2016

Subscribe to email list

Please select the email list(s) to which you wish to subscribe.

Publications by John Petkau

2018

Karim ME, Petkau J, Gustafson P, Platt RW, Tremlett H, Group BAMSStudy. Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies. Statistical Methods in Medical Research [Internet]. 2018;27 :1709-1722. http://journals.sagepub.com/doi/abs/10.1177/0962280216668554

2017

Karim ME, Petkau J, Gustafson P, Tremlett H, Group BAMSStudy. On the application of statistical learning approaches to construct inverse probability weights in marginal structural Cox models: Hedging against weight-model misspecification. Communications in Statistics - Simulation and Computation. 2017;46:7668-7697.
Högg T, Petkau J, Zhao Y, Gustafson P, Wijnands JMA, Tremlett H. Bayesian analysis of pair-matched case-control studies subject to outcome misclassification. Statistics in Medicine. 2017;36:4196-4213.
Zhang T, Kingwell E, Zhu F, Petkau J, Kastrukoff LF, Marrie RA, et al. Effects of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. British Medical Journal Open [Internet]. 2017;7:ID e018612, 7 pages. https://bmjopen.bmj.com/content/7/9/e018612
de Jong HJI, Kingwell E, Shirani A, Cohen-Tervaert JW, Hupperts R, Zhao Y, et al. Evaluating the safety of beta-interferons in multiple sclerosis: A series of nested case-control studies. Neurology. 2017;88:2310-2320.

2016

Karim ME, Gustafson P, Petkau J, Tremlett T. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. American Journal of Epidemiology. 2016;184:857-858.
Karim ME, Gustafson P, Petkau J, Tremlett H, Group BAMSStudy. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. American Journal of Epidemiology. 2016;184:325-335.
Zhang T, Kingwell E, DeJong HJI, Zhu F, Zhao Y, Carruthers R, et al. Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression. Pharmacoepidemiology and Drug Safety. 2016;25:1150-1159.

2015

Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, et al. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology. TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY: SPRINGER HEIDELBERG; 2015;262:2466-2471.
Reich DS, White R, Cortese ICM, Vuolo L, Shea CD, Collins TL, et al. Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging. Multiple Sclerosis Journal. 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD; 2015;21:1693-1704.
Kondo Y, Zhao Y, Petkau J. A flexible mixed-effect negative binomial regression model for detecting unusual increases in MRI lesion counts in individual multiple sclerosis patients. Statistics in Medicine. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL; 2015;34:2165-2180.
Shirani A, Zhao Y, Petkau J, Gustafson P, Karim ME, Evans C, et al. Multiple sclerosis in older adults: the clinical profile and impact of interferon beta treatment. BioMed Research International. 410 PARK AVENUE, 15TH FLOOR, \#287 PMB, NEW YORK, NY 10022 USA: HINDAWI PUBLISHING CORPORATION; 2015;2015:ID451912, 11 pages.
Zhao Y, Kondo Y, Traboulsee A, Li DKB, Riddehough A, Petkau AJ. Personalized activity index, a new safety monitoring tool for multiple sclerosis clinical trials. Multiple Sclerosis Journal – Experimental, Translational and Clinical [Internet]. 2015;1:1-15. http://mso.sagepub.com/content/1/2055217315577829
Zhang T, Shirani A, Zhao Y, Karim ME, Gustafson P, Petkau J, et al. Beta-interferon exposure and onset of secondary progressive multiple sclerosis. European Journal of Neurology [Internet]. 2015;22:990–1000. http://onlinelibrary.wiley.com/doi/10.1111/ene.12698/abstract

2014

Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, et al. Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiology and Drug Safety. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL; 2014;23:1213-1222.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Soelberg-Sorensen P, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA: LIPPINCOTT WILLIAMS & WILKINS; 2014;83:278-286.
Karim ME, Gustafson P, Petkau J, Zhao Y, Shirani A, Kingwell E, et al. Marginal structural Cox models for estimating the association between beta-interferon exposure and disease progression in a multiple sclerosis cohort. American Journal of Epidemiology. JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA: OXFORD UNIV PRESS INC; 2014;180:160-171.
Zhao Y, Li DKB, Petkau AJ, Riddehough A, Traboulsee A. Detection of unusual increases in MRI lesion counts in individual multiple sclerosis patients. Journal of the American Statistical Association [Internet]. 2014;109:119–132. http://amstat.tandfonline.com/doi/abs/10.1080/01621459.2013.847373

2013

Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al. Interferon beta and long-term disability in multiple sclerosis. JAMA Neurology. 515 N STATE ST, CHICAGO, IL 60654-0946 USA: AMER MEDICAL ASSOC; 2013;70:651-652.

2012

Shirani A, Petkau J, Tremlett H. Treatment with interferon beta for multiple sclerosis: reply. Journal of the American Medical Association. 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA: AMER MEDICAL ASSOC; 2012;308:1627-1628.
Altman RM, Petkau AJ, Vrecko D, Smith A. MRI-based clinical trials in relapsing-remitting multiple sclerosis: new sample size calculations based on a longitudinal model. Multiple Sclerosis Journal. 2012;18:1600–1608.
Tremlett H, Zhu F, Petkau J, Oger J, Zhao Y. Natural, innate improvements in multiple sclerosis disability. Multiple Sclerosis Journal. 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD; 2012;18:1412-1421.
Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. Journal of the American Medical Association. 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA: AMER MEDICAL ASSOC; 2012;308:247-256.
Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, et al. Neutralizing antibodies to interferon beta-1b in multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Multiple Sclerosis Journal. 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD; 2012;18:181-195.
Barkhof F, Simon JH, Fazekas F, Rovaris M, Kappos L, de Stefano N, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews Neurology. 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA: NATURE PUBLISHING GROUP; 2012;8:13-21.

2011

Riddell CA, Zhao Y, Li DKB, Petkau AJ, Riddehough A, Cutter GR, et al. Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis. Neurology [Internet]. 2011;77:2089–2096. http://www.neurology.org/content/77/24/2089
Hartung H-P, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, et al. Interferon β-1b–neutralizing antibodies 5 years after clinically isolated syndrome. Neurology [Internet]. 2011;77:835–843. http://www.neurology.org/content/77/9/835
Reingold SC, McFarland HF, Petkau AJ. The growing need for alternative clinical trial designs for multiple sclerosis. In Multiple Sclerosis Therapeutics. 4th ed. Cambridge: Cambridge University Press; 2011. pp. 253-260.
Brotto LA, Basson R, Petkau AJ, Labrie F. Predictors of sexual desire disorders in women. The Journal of Sexual Medicine. 2011;8:742–753.

2010

Zhao Y, Petkau AJ, Traboulsee A, Riddehough A, Li DKB. Does MRI lesion activity regress in secondary progressive multiple sclerosis?. Multiple Sclerosis [Internet]. 2010;16:434-442. http://msj.sagepub.com/content/early/2010/02/18/1352458509359726
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung H-P, Hemmer B, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurology. 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA: ELSEVIER SCIENCE INC; 2010;9:740-750.
Basson R, Brotto LA, Petkau AJ, Labrie F. Role of androgens in women's sexual dysfunction. Menopause. 75 YANAGINOBANBA NISHIIRU-MASUYA-CHO, SANJOU-DORI, NAKAGYOU-KU, KYOTO, 604-8111, JAPAN: JAPAN ENDOCRINE SOC; 2010;17:962-971.

2008

Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology [Internet]. 2008;70:1134–1140. http://www.neurology.org/content/70/13_Part_2/1134
Petkau J, Reingold SC, Held U, Cutter GR, Fleming TR, Hughes MD, et al. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Multiple Sclerosis [Internet]. 2008;14:770-778. http://msj.sagepub.com/content/early/2008/06/05/1352458507088104
Zhao Y, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology. AAN Enterprises; 2008;70:1092–1097.

2007

Ghement IR, Heckman NE, Petkau AJ. Seasonal confounding and residual correlation in analyses of health effects of air pollution. Environmetrics. Wiley Online Library; 2007;18:375–394.
Raffa JD, Grebely J, Tossonian H, Wong T, Viljoen M, Khara M, et al. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. Drug and Alcohol Dependence. Elsevier; 2007;89:306–309.

2006

Li DKB, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, et al. MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability. Neurology. AAN Enterprises; 2006;66:1384–1389.
Tremlett H, Seemüller S, Zhao Y, Yoshida EM, Oger J, Petkau J. Liver test abnormalities in multiple sclerosis: Findings from placebo-treated patients. Neurology. AAN Enterprises; 2006;67:1291–1293.

2005

Clayton MK, Petkau AJ. Evaluation of asymptotic approximations for a two-stage Bernoulli bandit. Journal of Statistical Planning and Inference. Elsevier; 2005;130:133–148.
Altman RM, Petkau AJ. Application of hidden Markov models to multiple sclerosis lesion count data. Statistics in Medicine. Wiley Online Library; 2005;24:2335–2344.
Barkhof F, Held U, Simon JH, Daumer M, Fazekas F, Filippi M, et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology. AAN Enterprises; 2005;65:1447–1454.

2004

Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Multiple Sclerosis. Sage Publications; 2004;10:126–138.
Vedal S, Rich K, Brauer M, White R, Petkau J. Air pollution and cardiac arrhythmias in patients with implantable cardioverter defibrillators. Inhalation Toxicology. Taylor & Francis; 2004;16:353–362.

Pages